MacroGenics Inc ((MGNX)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MacroGenics Inc. is conducting a Phase 1/1b clinical study titled ‘A Study of MGC026 in Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in patients with advanced solid tumors. This research is significant as it explores a potential new treatment option for patients with limited alternatives.
The intervention being tested is MGC026, a topoisomerase 1 inhibitor-based antibody-drug conjugate (ADC) targeting B7-H3. It is administered intravenously every three weeks to assess its effectiveness in treating solid tumors.
The study is designed as an interventional trial with a non-randomized, sequential model. There is no masking involved, and the primary purpose is treatment. This straightforward design allows for clear observation of the drug’s effects on participants.
The study began on March 6, 2024, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
The update on this study could influence MacroGenics’ stock performance positively if the results show promise, as it would enhance the company’s pipeline and attract investor interest. In the competitive landscape of oncology treatments, advancements in ADCs like MGC026 could position MacroGenics favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.